Investigational Drug Information for Radotinib
✉ Email this page to a colleague
What is the drug development status for Radotinib?
Radotinib is an investigational drug.
There have been 7 clinical trials for Radotinib.
The most recent clinical trial was a Phase 3 trial, which was initiated on December 28th 2018.
The most common disease conditions in clinical trials are Leukemia, Leukemia, Myeloid, and Leukemia, Myelogenous, Chronic, BCR-ABL Positive. The leading clinical trial sponsors are Il-Yang Pharm. Co., Ltd., Asan Medical Center, and Ulsan University Hospital.
Summary for Radotinib
US Patents | 0 |
International Patents | 0 |
US Patent Applications | 238 |
WIPO Patent Applications | 339 |
Japanese Patent Applications | 57 |
Clinical Trial Progress | Phase 3 (2018-12-28) |
Vendors | 48 |
Recent Clinical Trials for Radotinib
Title | Sponsor | Phase |
---|---|---|
Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease | Il-Yang Pharm. Co., Ltd. | Phase 2 |
Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China) | Il-Yang Pharm. Co., Ltd. | Phase 3 |
A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs | Il-Yang Pharm. Co., Ltd. | Phase 3 |
Clinical Trial Summary for Radotinib
Top disease conditions for Radotinib
Top clinical trial sponsors for Radotinib
US Patents for Radotinib
Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
---|---|---|---|---|
>Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |